AgomAb Therapeutics NV American Depositary Shares (AGMB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AgomAb Therapeutics NV American Depositary Shares (AGMB) has a cash flow conversion efficiency ratio of -0.085x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.44 Million) by net assets ($146.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AgomAb Therapeutics NV American Deposita (AGMB) net asset quality to measure how much of total assets are equity-financed.
AgomAb Therapeutics NV American Depositary Shares - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how AgomAb Therapeutics NV American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore AGMB long-term investment intensity to see how much of total assets are deployed in long-term investments.
AgomAb Therapeutics NV American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AgomAb Therapeutics NV American Depositary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MN Holdings Berhad
KLSE:0245
|
0.245x |
|
Cashway Technology Co Ltd
SHG:603106
|
-0.014x |
|
Jinxiandai Information Industry Co
SHE:300830
|
0.012x |
|
First Foundation Inc.
NYSE:FFWM
|
-0.027x |
|
SEC Electric Mach Co Ltd
SHG:603988
|
0.015x |
|
JPP Holding Company Limited
TW:5284
|
-0.008x |
|
Princess Private Equity Holding Ltd
LSE:PEY
|
0.029x |
|
Shandong Shengli Co Ltd
SHE:000407
|
0.110x |
Annual Cash Flow Conversion Efficiency for AgomAb Therapeutics NV American Depositary Shares (2022–2025)
The table below shows the annual cash flow conversion efficiency of AgomAb Therapeutics NV American Depositary Shares from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see market value of AgomAb Therapeutics NV American Deposita.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $130.90 Million | $-51.74 Million | -0.395x | -58.76% |
| 2024-12-31 | $188.08 Million | $-46.83 Million | -0.249x | -53.32% |
| 2023-12-31 | $151.44 Million | $-24.59 Million | -0.162x | +43.28% |
| 2022-12-31 | $66.25 Million | $-18.97 Million | -0.286x | -- |
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinica… Read more